Epigenetic priming to enhance CAR-T cell cytotoxicity in bladder cancer
Ontology highlight
ABSTRACT: We sought for new treatment strategies to improve response of urothelial carcinoma (UC) patients towards immune therapy. Epigenetic inhibitors may modulate expression of immune response regulators and alter the immune phenotype of UC cells. Thus, we determined whether longterm pretreatment of UC cell lines with the DNMT inhibitor decitabine (DEC) at low dosemight enhance killing by CAR-T cells. We engineered target-specific CAR-T cells recognizing EGFR and CD44v6 on UCC. To define underlying mechanisms we performed RNA Seq analysis for two UC cell lines treated accordingly.
ORGANISM(S): Homo sapiens
PROVIDER: GSE164862 | GEO | 2021/12/08
REPOSITORIES: GEO
ACCESS DATA